Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
280.01(c) 268.77(c) 267.12(c) 268.91(c) 266.8(c) Last
843 290 1 207 981 1 156 111 1 848 881 1 266 743 Volume
-0.22% -4.01% -0.61% +0.67% -0.78% Change
More quotes
Financials (USD)
Sales 2020 13 446 M - -
Net income 2020 4 465 M - -
Net Debt 2020 2 565 M - -
P/E ratio 2020 9,58x
Yield 2020 -
Sales 2021 11 574 M - -
Net income 2021 3 678 M - -
Net Debt 2021 132 M - -
P/E ratio 2021 10,4x
Yield 2021 -
Capitalization 41 380 M 41 380 M -
EV / Sales 2020 3,27x
EV / Sales 2021 3,59x
Nbr of Employees 7 400
Free-Float 86,4%
More Financials
Company
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (79.2%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (15.9%); - other (4.9%): primarily revenues from partnership agreements. 
Sector
Pharmaceuticals
Calendar
10/21Earnings Release
More about the company
Notations Surperformance© of Biogen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BIOGEN INC.
09:17aBIOGEN : Reports Q3 2020 Results
AQ
10/21BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/21BIOGEN : readies for U.S. launch of Alzheimer's drug ahead of FDA meeting
RE
10/21BIOGEN : Cuts Guidance Amid Competition From Generics
DJ
10/21BIOGEN : Posts Lower 4Q Profit as Pharmaceutical Revenue Declines
DJ
10/21BIOGEN INC. : Results of Operations and Financial Condition, Other Events, Finan..
AQ
10/21BIOGEN : readies for U.S. launch of Alzheimer's drug ahead of FDA meeting
RE
10/21BIOGEN : Reports Q3 2020 Results
PU
10/21BIOGEN : Reports Q3 2020 Earnings
PU
10/21BIOGEN : Q3 2020 Biogen Earnings Presentation
PU
10/20ABARCA : Details First Value-Based Agreement For Medicaid Members Prescribed Bio..
PR
10/16BIOGEN INC. : quaterly earnings release
10/08BIOGEN : to Report Third Quarter 2020 Financial Results October 21, 2020
AQ
10/07BIOGEN : Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Pr..
AQ
10/07BIOGEN : Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11
AQ
More news
News in other languages on BIOGEN INC.
10/21DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 21.10.2020 - 15.15 Uhr
10/21Biogen wird vorsichtiger wegen Konkurrenz bei Multiple-Sklerose-Mittel
10/21Aktien New York Ausblick: Stabil erwartet - Snap überzeugt, Netflix enttäusch..
10/21WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
10/21BIOGEN : abaissement des objectifs pour 2020
More news
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 296,46 $
Last Close Price 268,91 $
Spread / Highest target 43,5%
Spread / Average Target 10,2%
Spread / Lowest Target -15,2%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-9.38%42 572
CSL LIMITED7.46%96 217
SAMSUNG BIOLOGICS CO.,LTD.51.96%40 189
WUXI BIOLOGICS (CAYMAN) INC.126.25%39 434
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.208.12%38 977
ALEXION PHARMACEUTICALS, INC.14.66%25 904